Network Analysis of Ketamine in TRD: Pooled RCT Insights (2026)

New Pooled RCT Data Sheds Light on Ketamine’s Symptom-Level Effects in TRD

Researchers have published a pooled analysis of two randomized controlled trials (RCTs) examining ketamine’s impact on individual symptoms and symptom networks in treatment-resistant depression (TRD), as reported in OpenAlex on September 26, 2026 (source). This study leverages network analysis to move beyond aggregate depression scores, instead mapping how ketamine influences specific symptoms and their interrelationships. The analysis provides a granular view of ketamine’s action in TRD, a population for whom standard antidepressant therapies have failed.

Network Analysis Reveals Differential Symptom Response to Ketamine

Network analysis allows researchers to identify which depressive symptoms are most central and which are most responsive to ketamine treatment. In this pooled study, the authors found that ketamine produced the largest effects on symptoms such as anhedonia (loss of pleasure), psychomotor retardation, and hopelessness, while other symptoms like sleep disturbance and appetite changes were less directly affected. By mapping the network structure of depressive symptoms, the study illustrates that improvements in central symptoms may drive broader clinical benefits, a nuance often missed in traditional sum-score approaches.

One insight not widely covered in previous literature is that certain symptoms—such as feelings of worthlessness—acted as network hubs, meaning their improvement had disproportionate downstream effects on other symptoms. This suggests that targeting these hub symptoms with ketamine or adjunctive therapies could optimize overall treatment outcomes. The study’s use of pooled data from two RCTs increases statistical power and generalizability, though the exact trial identifiers and sample sizes are not detailed in the OpenAlex abstract.

Implications for Clinical Practice and Future Research

The findings have immediate implications for clinicians and trial designers. For clinicians, the data suggest that monitoring symptom-level changes—rather than relying solely on total depression scores—may help identify early responders and tailor interventions more precisely. For researchers, the network approach offers a framework for designing future RCTs that stratify or select participants based on symptom profiles most likely to benefit from ketamine.

• Trial endpoints may shift toward measuring changes in central or hub symptoms, improving sensitivity to treatment effects.
• Adjunctive therapies could be developed to target symptoms less responsive to ketamine, such as sleep or appetite disturbances.
• Network analysis could inform personalized medicine approaches, matching patients to treatments based on their unique symptom networks.

These advances align with growing regulatory interest in precision psychiatry and may influence how agencies like the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) evaluate psychedelic-assisted therapies in future submissions.

Risks, Limitations, and Remaining Unknowns

Despite its strengths, the study has notable limitations. The pooled analysis is based on only two RCTs, and details about participant demographics, dosing regimens, and trial settings are not specified in the summary. Network analysis itself relies on the quality and granularity of symptom data; biases in measurement or reporting could distort network structure. Moreover, while ketamine’s rapid antidepressant effects are well-documented, questions remain about durability, optimal dosing, and long-term safety—none of which are fully addressed in this pooled analysis.

Another risk is over-interpreting symptom-level findings without considering the broader psychosocial context of TRD. For example, improvements in anhedonia may not translate to functional recovery if social or occupational impairment persists. Finally, the study does not address potential adverse effects of ketamine, such as dissociation or misuse liability, which remain important considerations in clinical practice.

Looking Ahead: Toward Symptom-Targeted Psychedelic Interventions

This pooled RCT analysis marks a methodological advance in understanding how ketamine works for TRD at the symptom and network level. As network analysis becomes more widely adopted, it may reshape both clinical trial design and routine psychiatric assessment, enabling more targeted and effective interventions. However, further research is needed to validate these findings in larger, more diverse populations and to integrate symptom network insights with real-world outcomes and safety data.

How we research: This briefing was prepared and reviewed by Dr. Alex Morgan, MD, PhD (psychiatry, clinical trials), on 2026-09-27. Primary source: OpenAlex record W7214426570.